Treatment of Neuromyelitis Optica with Mycophenolate Mofetil in Japanese Patients

Treatment of Neuromyelitis Optica with Mycophenolate Mofetil in Japanese Patients - An open treatment trial of NMO with MMF

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031135

Enrollment

Registered

2018-04-01

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromyelitis Optica

Interventions

Mycophenolate mofetil treatment for 1 year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Stable Neuromyelitis Optica patients with EDSS score less than 7.0 who wish to participate in this study

Exclusion criteria

Exclusion criteria: 1. Patients with infection 2. Patients with pregnancy or breast-feeding 3. Patients who take any immunosuppressant other than steroid 4. patients with severe liver or kidney dysfunction 5. patients with a history of cancer within 5 years 6. In addition, patients judged inappropriate by the investigators

Design outcomes

Primary

Measure	Time frame
Assess the effect of Mycophenolate mofetil suppressing the recurrence of Neuromyelitis optics for 1 year	—

Countries

Japan

Contacts

Public ContactNorio Chihara

Kobe University Hospital Neurology

med3@med.kobe-u.ac.jp078-382-5885

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026